News & Updates

The coronavirus disease 2019 (COVID-19) pandemic has led to a sharp decline in treatment for older patients with newly diagnosed cancers of the digestive system, a recent study has found.

Several disease-modifying therapies (DMTs) for multiple sclerosis (MS) do not pose an increased risk of cancer, a study has shown.

Use of opioids in the long term leads to shorter length of stay (LOS) and reduced inpatient mortality among patients hospitalized with nonmetastatic colorectal cancer (CRC), results of a study have shown. However, patients with cancer-related complications endure longer LOS and higher mortality than those admitted without such morbidities.

The time elapsed between diagnosis of rectal cancer and initiation of neoadjuvant chemoradiation (NCRT) shows a significant association with pathologic complete response (pCR), and shortening this time may improve the likelihood of achieving pCR, suggests a recent study.

Prior history of ischaemic stroke appears to affect the risk of ischaemic stroke in patients newly diagnosed with cancer, according to a study from Canada presented at ASH 2021.

In a phase II study, the novel oral HIF*-2α inhibitor belzutifan showed promise for individuals with renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease, a rare autosomal dominant hereditary disease associated with benign and malignant neoplasms, including clear-cell RCC, pancreatic neuroendocrine tumours, and CNS** and retinal hemangioblastomas.